A recurrent pathogenic BRCA2 exon 5–11 duplication in the Christian Arab population in Israel
Familial Cancer · 2022-07 · 21 (3) · 289-294
DOI: 10.1007/s10689-021-00262-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Familial Cancer, online erschienen am 17.05.2021. Verfasst von Gili Reznick Levi und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Genetics Institute, Rambam Health Care Campus, Haifa, Israel. g_reznick@rambam.health.gov.il. Hauptthemen laut MEDLINE: BRCA2 Protein, Breast Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Germline pathogenic variants (PVs) in BRCA1/BRCA2 are well-established risk factors for breast cancer (BC) and/or ovarian cancer (OC). Founder PVs have been described in BRCA1/ BRCA2 in several genetic isolates. The Christian Arab population in the Middle East is a relatively isolated ethnic group, yet founder, or recurrent BRCA1/BRCA2 PVs have not been reported in this population. In this study we describe PVs detected in cancer susceptibility genes among a cohort of Christian Arabs from Israel. We reviewed patient records from the Oncogenetic clinic at Rambam Health Care Campus during the years 2013- mid 2020. Thirty-five unrelated Christian Arab patients, with personal or family history of BC and/or OC underwent BRCA1/BRCA2 (14/35) testing or cancer gene panel testing (21/35) as part of their diagnostic workup. Three clinically significant variants in BRCA2, CHEK2 and RAD51C were found in 7/35 patients (20%). A recurrent duplication of the BRCA2 genomic region, encompassing exons 5-10 and the 5' portion of exon 11, was found in 5/33 (15.2%) patients for whom copy number variants (CNVs) analysis was performed. We identified a recurrent pathogenic BRCA2 duplication in Christian Arab patients with a personal/ family history of BC and/or OC. Our findings emphasize the importance of inclusion of CNVs analysis in BRCA1/BRCA2 genetic testing, and specifically for Christian Arab patients suspected of hereditary BC and/or OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Genetics Institute, Rambam Health Care Campus, Haifa, Israel. g_reznick@rambam.health.gov.il.
- The Genetics Institute, Rambam Health Care Campus, Haifa, Israel.
- The Genetics Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Institute of Medical Genetics, Meir Medical Center, Kfar Saba, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Zitieren
APA
Reznick Levi, G., Larom, G., Ofen Glassner, V., Ekhilevitch, N., Sharon Swartzman, N., Paperna, T., Baris-Feldman, H., & Weiss, K. (2022). A recurrent pathogenic BRCA2 exon 5–11 duplication in the Christian Arab population in Israel. Familial Cancer, 21(3), 289-294. https://doi.org/10.1007/s10689-021-00262-0
Vancouver
Reznick Levi G, Larom G, Ofen Glassner V, Ekhilevitch N, Sharon Swartzman N, Paperna T, et al. A recurrent pathogenic BRCA2 exon 5–11 duplication in the Christian Arab population in Israel. Familial Cancer. 2022;21(3):289-294. doi:10.1007/s10689-021-00262-0
BibTeX
@article{ReznickLevi2022,
author = {Reznick Levi, Gili and Larom, Gal and Ofen Glassner, Vered and Ekhilevitch, Nina and Sharon Swartzman, Nitzan and Paperna, Tamar and Baris-Feldman, Hagit and Weiss, Karin},
title = {A recurrent pathogenic BRCA2 exon 5–11 duplication in the Christian Arab population in Israel},
journal = {Familial Cancer},
year = {2022},
volume = {21},
number = {3},
pages = {289--294},
doi = {10.1007/s10689-021-00262-0}
}
EUVIMED